CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 440 enrolled
Drug / intervention
Reverse hybrid therapy +1 moredrug
Likely dose
Reverse hybrid therapy 40 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02359435
NCT02359435N/ACompleted

Comparison of 12-day Reverse Hybrid Therapy and 12-day Standard Triple Therapy for Helicobacter Pylori Infection - a Randomized Controlled Trial (REHYTRI Study)

Kaohsiung Veterans General Hospital.·interventional·Posted Feb 10, 2015·Updated Apr 18, 2017

In Brief

A clinical study evaluating Reverse hybrid therapy and Standard triple therapy for Helicobacter Pylori Infection. Completed, enrolled 440 participants across 1 site.

Detailed Summary

Reverse hybrid therapy is a one-step two-phase treatment for Helicobacter pylori infection with less cost than standard triple therapy. Whether reverse hybrid therapy can replace standard triple therapy as the recommended first-line treatment is unknown. The investigators compared the efficacy of 12-day reverse hybrid therapy and 12-day standard triple therapy in first-line treatment.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesTaiwan

Timeline

N/ACompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedFeb 10, 2015
Enrollment StartOct 1, 2012
Primary CompletionFeb 1, 2015
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 11.4 years ago

Interventions

Reverse hybrid therapydrug

pantoprazole 40 mg b.d., amoxicillin 1 g b.d., clarithromycin 500 mg b.d. and metronidazole 500 mg b.d. for the first 7 days, followed by pantoprazole 40 mg b.d. and amoxicillin 1 g b.d. for another 5 days

Standard triple therapydrug

pantoprazole 40 mg b.d., clarithromycin 500 mg b.d., and amoxicillin 1 g b.d. for 12 days